

This facsimile message and its contents are legally privileged and confidential information intended solely for the use of the addressee. If the reader of this message is not the intended recipient, you are hereby notified that any dissemination, distribution, copying or other use of this message and its contents is strictly prohibited. If you have received this telecopy in error, please notify us immediately by telephone and return the original message to us at the address shown below via the Postal Service. Thank You.

ALSTON & BIRD LLP

3201 Beechleaf Court, Suite 600
Raleigh, NC 27604-1062
919-862-2200
Fax: 919-862-2260

TELECOPY PLEASE DELIVER AS SOON AS POSSIBLE

Date:

November 4, 2008

Recipient:

Mi Qiuwen, Group Art Unit: 1655

Company:

U.S. Patent Office

Fax Number:

571-273-5984

Voice Number:**Sender:**

Edward R. Ergenzinger

Message:

Number of Pages: (including cover page) 4

IF NOT RECEIVED PROPERLY, PLEASE NOTIFY US IMMEDIATELY AT 919-862-2233.

USER CODE:	CAPOM	REQUESTED BY:	Michele Capozzi
CLIENT/MATTER:		OPERATOR:	

Attorney's Docket No. 033794/307767

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re: Filho et al. Confirmation No.: 7174
Appl. No.: 10/567,899 Group Art Unit: 1655
Filed: August 10, 2006 Examiner: Qiuwen, Mi
For: PHARMACEUTICAL COMPOSITION COMPRISING PLANT MATERIAL OR
TRICHILIA SP. ALONG OR IN ASSOCIATION WITH OTHER PLANT
EXTRACTS FOR THE REVERSION/COMBAT AND/OR PREVENTION OF
VENTRICULAR FIBRILLATION

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUBMISSION OF TERMINAL DISCLAIMER
UNDER 37 C.F.R. § 1.321(c)

Applicant hereby submits the enclosed Terminal Disclaimer Under 37 C.F.R. § 1.321(c) for the above referenced application. The Examiner is authorized to charge the amount of \$140.00 for a large entity [37 C.F.R. 1.20(d)] to cover the fee for filing a Terminal Disclaimer. Also, the Examiner is authorized to charge Deposit Account No. 16-0605 for any additional fee that may be required or credit any overpayment.

Respectfully submitted,

/edward r. ergenzinger/

Edward R. Ergenzinger
Registration No. 47,549

CUSTOMER NO. 00826
ALSTON & BIRD LLP
Bank of America Plaza
101 South Tryon Street, Suite 4000
Charlotte, NC 28280-4000
Tel Raleigh Office (919) 862-2200
Fax Raleigh Office (919) 862-2260

ELECTRONICALLY FILED USING THE EFS-WEB ELECTRONIC FILING SYSTEM OF THE UNITED STATES PATENT & TRADEMARK OFFICE AND BY FACSIMILE TO 571-273-5984 ON November 4, 2008.

In re: Filho et al.
Appl. No.: 10/567,899
Filing Date: August 10, 2006
Page 2

Nothing herein shall be construed as a disclaimer of any terminal part of any patent granted on the above-identified application which is prior to the expiration of the full statutory term of U.S. Patent No. 12/100,834 in the event that it later expires for failure to pay a maintenance fee, is held unenforceable, is found invalid, is statutorily disclaimed in whole or terminally disclaimed under 37 CFR 1.321(c), has all claims canceled by a reexamination certificate, or is otherwise terminated prior to expiration of its statutory term as presently shortened by any terminal disclaimer, except for the separation of legal title stated above.

Respectfully submitted,



Date: 11/4/08

Edward R. Ergenzer
Registration No. 47,549

Customer No. 00826
ALSTON & BIRD LLP
Bank of America Plaza
101 South Tryon Street, Suite 4000
Charlotte, NC 28280-4000
Tel Raleigh Office (919) 862-2200
Fax Raleigh Office (919) 862-2260

Attorney's Docket No. 033794/307767

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re: Filho et al. Confirmation No.: 7174
Appl. No.: 10/567,899 Group Art Unit: 1655
Filed: August 10, 2006 Examiner: Qiuwen, Mi
For: PHARMACEUTICAL COMPOSITION COMPRISING PLANT MATERIAL OR
TRICHLIA SP. ALONE OR IN ASSOCIATION WITH OTHER PLANT
EXTRACTS FOR THE REVERSION/COMBAT AND/OR PREVENTION OF
VENTRICULAR FIBRILLATION

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

TERMINAL DISCLAIMER UNDER 37 C.F.R. 1.321(c)

I, Edward R. Ergenzinger, am an attorney of record of the disclaimant, Laboratorio Catarinense S'A, and am authorized to execute this disclaimer on behalf of Laboratorio Catarinense S'A. The disclaimant, Laboratorio Catarinense S/A, having a principal place of business at Rua Dr. Joao Colin 1053, Joinville - SC, Brazil 89200, is the owner of all right, title and interest in the above-identified application, by Assignment filed October 12, 2006, and recorded at Reel 018382, Frame 0127.

The disclaimant hereby disclaims the terminal part of any patent granted on the above-identified application which would extend beyond the expiration date of the full statutory term of United States Patent No. 12/100,834, filed April 10, 2008, entitled "Pharmaceutical Composition Comprising Plant Material or Trichilia Sp. Alone or in Association with Other Plant Extracts for the Reversion/Combat and/or Prevention of Ventricular Fibrillation", which patent was assigned to the above-identified disclaimant by an Assignment recorded October 12, 2006, at Reel 018382, Frame 0127.

Disclaimant further agrees that any patent so granted on the above-identified application, which is the subject of this disclaimer, shall be enforceable only for and during such period that the legal title to said patent shall be the same as the legal title to U.S. Patent No. 12/100,834, this agreement to run with any patent granted on the above-identified application and to be binding upon the grantee, its successors, or assigns.

1 EGA1.02/31014376v1